Background: Heroin craving is a trigger for relapse and dropping out of treatment. Methadone has been the standard medication for the management of heroin craving.
Objectives: We explored the medication options other than methadone which may have heroin anticraving properties.
Methods: To be selected for the review, articles had to include outcome measures of the effect of the studied medication on subjective and/or objective opiate craving and be of the following two types: (1) randomized, controlled, and/or double-blind clinical trials (RCTs) examining the relationship between the studied medication and heroin craving; (2) nonrandomized and observational studies (NRSs) examining the relationship between the studied medication and heroin craving. Thirty-three articles were initially included in the review. Twenty-one were excluded because they did not meet the inclusion criteria. We present the results of 12 articles that met all the inclusion criteria.
Results: Some new medications have been under investigation and seem promising for the treatment of opiate craving. Buprenorphine is the second most studied medication after methadone for its effect on opiate craving. At doses above 8 mg daily, it seems very promising and practical for managing opiate craving in patients receiving long-term opioid maintenance treatment.
Conclusions And Scientific Significance: In doses higher than 8 mg daily, buprenorphine is an appropriate treatment for opiate craving. More research with rigorous methodology is needed to study the effect of buprenorphine on heroin craving. Also more studies are needed to directly compare buprenorphine and methadone with regard to their effects on heroin craving.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3109/00952990.2010.505991 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Opioid use and abuse in adolescents and young adults; dealing with science, laws and ethics: Charming the COBRAS.
Dis Mon
January 2025
Department of Pediatric and Adolescent Medicine, Western Michigan University, Homer Stryker M.D. School of Medicine, Kalamazoo, MI, USA.
The subject of substance use disorders in the pediatric population remains a disturbing conundrum for clinicians, researchers and society in general. Many of our youth are at risk of being damaged and even killed by drug addictions that result from the collision of rapidly developing as well as vulnerable central nervous systems encountering the current global drug addiction crisis. A major motif of this chemical calamity is opioid use disorder in adolescents and young adults that was stimulated by the 19th century identification of such highly addictive drugs as morphine, heroin and a non-opiate, cocaine.
View Article and Find Full Text PDFPomegranate juice ameliorates craving and oxidative stress on patients under medication for opioid addiction treatment with methadone and buprenorphine: A ranzomised controlled trial.
Clin Nutr ESPEN
January 2025
Department of Nutrition and Dietetics, University of Thessaly, Trikala, Argonafton 1, 42132 Trikala, Greece. Electronic address:
Background & Aims: Buprenorphine and methadone are drugs used as medication for addiction treatment for patients with opioid use disorders (OUDs). However, scarce evidence indicates that they induce oxidative stress, which contributes to the deterioration of psychosocial parameters, thus complicating successful rehab. Therefore, a dietary antioxidant intervention such as pomegranate could be beneficial for that group of patients.
View Article and Find Full Text PDFA pilot study on craving and its relationship to self-ratings of depression and anxiety in prescription opioid use disorder.
Exp Clin Psychopharmacol
January 2025
Substance Use and Concurrent Disorders Program, Royal Ottawa Mental Health Centre.
The role of craving in opioid use disorder (OUD) has been well established with respect to heroin but less so with prescription opioids. This pilot study, conducted in 18 treatment-seeking patients with prescription OUD and 18 healthy volunteers, assessed spontaneous (in the moment) and cue-induced craving and their relationship to depression and anxiety. Patients (vs.
View Article and Find Full Text PDFDisrupting heroin-associated memory reconsolidation through actin polymerization inhibition in the nucleus accumbens core.
Int J Neuropsychopharmacol
December 2024
National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China.
Background: Understanding drug addiction as a disorder of maladaptive learning, where drug-associated or environmental cues trigger drug cravings and seeking, is crucial for developing effective treatments. Actin polymerization, a biochemical process, plays a crucial role in drug-related memory formation, particularly evident in conditioned place preference paradigms involving drugs like morphine and methamphetamine. However, the role of actin polymerization in the reconsolidation of heroin-associated memories remains understudied.
View Article and Find Full Text PDFFrontal White Matter Changes and Craving Recovery in Inpatients With Heroin Use Disorder.
JAMA Netw Open
December 2024
Departments of Psychiatry and Neuroscience, Icahn School of Medicine at Mount Sinai, New York City, New York.
Importance: Amidst an unprecedented opioid epidemic, identifying neurobiological correlates of change with medication-assisted treatment of heroin use disorder is imperative. White matter impairments in individuals with heroin use disorder (HUD) have been associated with drug craving, a reliable predictor of treatment outcomes; however, little is known about structural connectivity changes with inpatient treatment and abstinence in individuals with HUD.
Objective: To assess white matter microstructure and associations with drug craving changes with inpatient treatment in individuals with HUD (effects of time and rescan compared with controls).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!